Article Text

Download PDFPDF
Novel treatment (new drug/intervention; established drug/procedure in new situation)
Significant hypotension following buccal midazolam administration
  1. Maria Kensche1,2,
  2. Josemir W Sander1,2,
  3. Sanjay M Sisodiya1,2
  1. 1Institute of Neurology, University College London, London, UK
  2. 2The National Society for Epilepsy, Chalfont St Peter, Buckinghamshire, UK
  1. Correspondence to Maria Kensche, maria.kensche{at}charite.de

Summary

Buccal midazolam is a rescue medication to reduce the duration of or stop an epileptic seizure, and is used to prevent status epilepticus. It is available in various forms, including a buccal preparation with a strength of 10 mg/1 ml. Midazolam is a licensed medication, but the buccal formulation is currently used off-licence. The prescriber takes ultimate responsibility for its use in this way. Administered by a trained person, it is receiving widespread acceptance as an alternative and effective treatment to rectally-administered diazepam in the community. The commonest side effects of midazolam are drowsiness and somnolence, although respiratory depression and paradoxical reactions, for example, agitation, restlessness and disorientation, may also occur. Hypotension is said to be a rare side effect, but with no reported cases in people administered buccal midazolam. The authors report a case of significant hypotension associated with administration of buccal midazolam for seizure management.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Competing interests None.

  • Patient consent Obtained.